General Information of Drug (ID: DMP8QY2)

Drug Name
M1774 Drug Info
Synonyms
674783-97-2; 9-Mesityl-10-methylacridinium Perchlorate; 10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium;perchlorate; MFCD09038536; Acridinium, 10-methyl-9-(2,4,6-trimethylphenyl)-, perchlorate; ACMC-209nz7; 9-Mesityl-10-methyl-10-acridinium Perchlorate; [Acr-Mes]+(ClO4)-; SCHEMBL10009695; 10-Methyl-9-(2,4,6-trimethylphenyl)acridinium Perchlorate; DTXSID60580419; ANW-35345; AKOS015843774; SY076797; 9-mesityl-10-methyl-acridinium perchlorate; CS-0103389; 9-Mesityl-10-methylacridin-10-ium perchlorate; 9-Mesityl-10-methylacridinium perchlorate, 95%; 9-Mesityl-10-methylacridinium perchlorate, AldrichCPR; 10-METHYL-9-(2,4,6-TRIMETHYLPHENYL)ACRIDIN-10-IUM PERCHLORATE
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
PubChem CID
15953479
CAS Number
CAS 674783-97-2
TTD Drug ID
DMP8QY2

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AZD6738 DM0PFNC Small-cell lung cancer 2C25.Y Phase 2 [3]
RP-3500 DM9FNC8 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [4]
Camonsertib DMOPPXY Aggressive cancer 2A00-2F9Z Phase 1/2 [5]
BAY1895344 DML781M Lymphoma 2A80-2A86 Phase 1 [6]
VX-970 DMR9PCT Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
M4344 DMQBO3V Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
CGK733 DM8OAN9 Discovery agent N.A. Investigative [8]
AZ20 DMNQ3HV Discovery agent N.A. Investigative [9]
VE-821 DM0UXNF Solid tumour/cancer 2A00-2F9Z Investigative [7]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Serine/threonine-protein kinase ATR (FRP1) TT8ZYBQ ATR_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04170153) M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors. U.S. National Institutes of Health.
2 National Cancer Institute Drug Dictionary (drug name M1774).
3 National Cancer Institute Drug Dictionary (drug id 754022).
4 Clinical pipeline report, company report or official report of Repare Therapeutics.
5 Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun;29(6):1400-1411.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
8 Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74.
9 Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013 Mar 14;56(5):2125-38.